171 related articles for article (PubMed ID: 16574044)
21. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
Dahabreh IJ; Economopoulos K
Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
[TBL] [Abstract][Full Text] [Related]
23. [The FIELD study presented and published. Unconvincing results of fenofibrates in diabetic patients].
Widimský J
Vnitr Lek; 2006 Jan; 52(1):80-4. PubMed ID: 16526203
[TBL] [Abstract][Full Text] [Related]
24. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
25. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
26. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study.
Ye P; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC;
J Am Geriatr Soc; 2007 Jul; 55(7):1015-22. PubMed ID: 17608873
[TBL] [Abstract][Full Text] [Related]
27. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
28. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R; Kupfer S; Erdmann E;
Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
[TBL] [Abstract][Full Text] [Related]
29. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
Sacks FM
Am J Cardiol; 2008 Dec; 102(12A):34L-40L. PubMed ID: 19084088
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
31. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
Andraws R; Brown DL
Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
[TBL] [Abstract][Full Text] [Related]
32. Expert commentary: the safety of fibrates in lipid-lowering therapy.
Brown WV
Am J Cardiol; 2007 Mar; 99(6A):19C-21C. PubMed ID: 17368273
[TBL] [Abstract][Full Text] [Related]
33. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
Pinelli NR; Cha R; Brown MB; Jaber LA
Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
[TBL] [Abstract][Full Text] [Related]
34. Fibrates after the FIELD study: Some answers, more questions.
Wierzbicki AS
Diab Vasc Dis Res; 2006 Dec; 3(3):166-71. PubMed ID: 17160911
[TBL] [Abstract][Full Text] [Related]
35. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials.
Hopper I; Billah B; Skiba M; Krum H
Eur J Cardiovasc Prev Rehabil; 2011 Dec; 18(6):813-23. PubMed ID: 21878448
[TBL] [Abstract][Full Text] [Related]
36. [On behalf and the extent of evidence].
Ruiz J
Rev Med Suisse; 2010 Jun; 6(252):1171-2. PubMed ID: 20614750
[No Abstract] [Full Text] [Related]
37. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Arora RR
Int J Cardiol; 2010 May; 141(2):157-66. PubMed ID: 19232762
[TBL] [Abstract][Full Text] [Related]
38. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.
Turnbull F; Neal B; Algert C; Chalmers J; Chapman N; Cutler J; Woodward M; MacMahon S;
Arch Intern Med; 2005 Jun; 165(12):1410-9. PubMed ID: 15983291
[TBL] [Abstract][Full Text] [Related]
39. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
Ametov AS; P'ianykh OP; Chernikova NA
Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
[TBL] [Abstract][Full Text] [Related]
40. Effect of angiotensin receptor blockers in the prevention of type 2 diabetes and cardiovascular events: a meta-analysis of randomized trials.
Song HF; Wang S; Li HW
Chin Med J (Engl); 2012 May; 125(10):1804-10. PubMed ID: 22800904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
